Introduction
Malignant gliomas account for the largest number of human malignant brain tumors and are considered incurable (Schoenberg, 1983) . The in®ltrative growth pattern of these tumors precludes curative neurosurgery, and tumor cells fail to respond to irradiation, chemotherapy, or immunotherapy (Mahalty et al., 1989) . Life expectancy after diagnosis can be as little as 6 months and rarely greater than 12 months (Deen et al., 1993) . Therefore, in order to improve the prognosis in this invariably fatal disease, it will be essential to explore novel forms of treatment. Recently it was shown that 70 ± 80% of tumors, including malignant gliomas, show very high levels of expression of telomerase, whereas, with a few exceptions, normal cells do not (Counter et al., 1992; Kim et al., 1994; Broccoli et al., 1995; Hiyama et al., 1995; Langford et al., 1995) . Telomerase is the ribonucleoprotein enzyme complex that elongates telomeric DNA (TTAGGG) n (Blackburn, 1991) and is now thought to be an important step in the development of cellular immortality and oncogenesis (de Lange et al., 1994) . Its almost exclusive expression in tumor cells potentially makes it a very strong candidate for targeted therapy, particularly for brain tumor patients where there are currently few, if any, alternatives. Cultured malignant glioma cells express telomerase, whereas cultured astrocytes and low grade astrocytoma do not (Kondo et al., unpublished data) . To investigate the eect of blocking telomerase activity on the growth of tumor cells, we previously transfected the antisense vector for the human telomerase RNA component (hTR) into human malignant glioma cells (Kondo et al., 1997) . The cell growth capacity of these cells was greatly reduced and, unlike the parental cells, they were unable to form tumors in nude mice. Challenging the RNA component of telomerase with antisense oligonucleotides, therefore, appeared to be a rational approach for the treatment of malignant gliomas.
We have now developed this concept further by using chimeric oligonucleotides which induce the active degradation of hTR. 2-5A antisense refers to a class of oligonucleotide therapeutic agents that cause the catalytic breakdown of target RNA molecules Maran et al., 1994; Maitra et al., 1995; Cirino et al., 1997) . These drugs contain a 2',5'-linked tetraadenylate (2-5A) covalently attached through linkers to antisense oligonucleotides. 2-5A is the activator of RNase L, a single-strand speci®c endoribonuclease that functions in the antiviral mechanisms of interferon action (Clemens and Williams, 1978; Zhou et al., 1993; Silverman, 1997) . RNase L is a ubiquitous protein that has no detectable ribonuclease activity until it comes into contact with 2-5A. Attachment of 2-5A to antisense oligonucleotides greatly enhances the degradation rates of target RNA molecules in intact, human cells (Maran et al., 1994; Cirino et al., 1997) . In essence, the 2-5A component of the oligonucleotide activates RNase L while the antisense segment of the chimera directs RNase L to the target RNA molecule. For example, unfacilitated uptake of 2-5A antisense into human HeLa cells resulted in the ablation of a cellular mRNA for protein kinase PKR (Maran et al., 1994) . Recently, the recruitment of RNase L by 2-5A antisense to a respiratory syncytial virus (RSV) mRNA resulted in a potent inhibition of RSV replication in human tracheal epithelial cells (Cirino et al., 1997) . Antisense molecules`charged' by the addition of a functional, tetrameric 2-5A were eective against RSV replication whereas antisense molecules containing a nonfunctional, dimeric 2-5A moiety were ineective (Cirino et al., 1997) . Because RNase L is present in nearly all mammalian cells, it is clear that the application of this technology is a powerful method for preventing gene expression.
In this report we demonstrate that, by treating malignant glioma cells in culture with 2-5A-antisense against telomerase RNA the vast majority of cells can be killed within 14 days. Furthermore, when the antisense molecules are injected directly into tumors induced subcutaneously in nude mice, the tumor mass is signi®cantly reduced by 50% over a 14 day period.
Results

Design of the antisense oligonucleotide
For successful application of this antisense technology, it is essential to construct antisense oligonucleotides against an`open' part of the RNA molecule to ensure the maximum likelihood of achieving homologous binding. To determine the best target sequence, therefore, the telomerase RNA (hTR) structure was analysed using the MFOLD program (Salser, 1978; Zuker, 1989; Frier et al., 1986) . The predicted structure of the telomerase RNA showed that this molecule had very tight secondary folding which would make the binding of small oligonucleotides dicult (Figure 1 ).
The most`open' part of the molecule is seen between residues 76 and 94, 20 nucleotides 3' of the telomerase template sequence. Therefore, we designed the 2-5A antisense oligonucleotide against the predicted loop comprising nucleotides 76 ± 94. BLASTN searches of available databases for this nucleotide sequence only revealed homologies to the human hTR and a DNA sequence from H. in¯uenzae. To investigate the eect of 2-5A antisense against hTR on malignant glioma cells, we synthesized spA 4 -anti-hTR, with complete homology to the targeted sequence, as well as two control oligonucleotides; spA 2 -anti-hTR, and spA 4 -anti-(M6)hTR (Table 1) . To establish the contribution of the 2-5A moiety of the chimeras to the antitelomerase eects, spA 2 -anti-hTR contains only two 2',5'-linked adenylyl residues instead of the usual four (Table 1 ). Chains of three or more 2',5'-linked adenylyl residues are absolutely required for RNase L activation, and so dimeric forms of 2-5A are inactive (reviewed in Silverman et al., 1997) . Another control oligonucleotide, spA 4 -anti-(M6)hTR, contains functional tetrameric 2-5A, but there are six mismatched nucleotides in the antisense cassette of the chimera which would reduce or prevent binding with the telomerase RNA. All three oligonucleotides contained stabilizing modi®cations at both termini. The 5' termini contain a thiophosphate to protect against phosphatase activity and the opposite termini contain a 3',3' Figure 1 Predicted MFOLD secondary structure of the human telomerase RNA which has a DG of 7168 kcal per mole. The positions of the telomerase template (nucleotides 46 ± 56) and the sequence used to design the antisense oligonucleotides (nucleotides 76 ± 94) are indicated by the arrows Oligonucleotide: Sequence
Bu-butanediol linkers; underline indicates mismatched nucleotides
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RTLGA GB-1 U251 T98G U373 Figure 2 Autoradiograph following the TRAP assay using extracts of cultured astrocytes (P1N), low grade astrocytoma (RTLGA), and malignant glioma cells (GB-1, U251-MG, T98G, and U373-MG).
Only the glioma cells demonstrate telomeraseactivity 2-5A antisense therapy for malignant gliomas S Kondo et al inverted linkage to inhibit 3' and 5' exonuclease activities Xiao et al., 1994 Xiao et al., , 1996 Cirino et al., 1997) .
Eect of antisense telomerase in vitro
Because of our special interest in developing an alternative strategy for the treatment of malignant brain tumors we concentrated our eorts, in the ®rst instance, on cell lines derived from these tumors. Since the strategy was to determine the eect of inactivating telomerase RNA on cell growth and malignancy we ®rst established the telomerase expression pro®le in a number of generally available glioma cell lines using the TRAP assay. The results are shown in Figure 2 .
Cell extracts which produce a ladder of extended oligonucleotides with increasing sizes indicate the presence of telomerase activity (see Materials and methods section). In this survery the four cell lines showing telomerase activity were all derived from malignant gliomas, whereas cells from normal astrocytes (P1N) and low grade astrocytomas (RTLGA) were apparantly telomerase negative. We have since established this correlation in cells from primary brain tumor tissue, with only malignant gliomas showing telomerase activity. For our initial studies, therefore, we selected U251-MG cells for antisense treatment because they had the highest level of telomerase activity. Previous experience with targeting the PKR mRNA (Maran et al., 1994) and an RSV mRNA (Cirino et al., 1997) using speci®c 2-5A-linked oligonucleotides had demonstrated that the target RNA was degraded after 4 ± 5 h. We therefore treated aliquots of U251-MG cells with the`active' oligonucleotide and the two controls for 5 h. RNA was then prepared from these cells and subjected to RT ± PCR to detect telomerase RNA. GAPDH mRNA was used to demonstrate a lack of non-speci®c activity of these oligonucleotides in these cells. As seen in Figure 3 , cells treated with spA 4 -antihTR had no detectable telomerase RNA after 5 h treatment. In contrast, telomerase RNA (hTR) was present in cells treated with the control oligonucleotides; spA 2 -anti-hTR and spA 4 -anti-(M6)hTR. Thus, we could selectively destroy hTR in U251-MG cells. Since the RT ± PCR assay is not quantitative, we were unable to assess whether treatment with the spA 2 -antihTR, which has the fully complementary target sequence, had any antisense eect by itself. From these experiments it was clear, however, that the speci®c action of spA 4 -anti-hTR was dependent upon both functional 2-5A and a genuine antisense eect.
Knowing that hTR could be inactivated by the 2-5A antisense treatment, we next treated U251-MG cells every 12 h over a 14 day period with the same three oligonucleotides. Cell viability was assessed every 2 days and the results are shown in Figure 4 . Seventynine per cent of the cells treated with spA 4 -anti-hTR were killed over the 14 day period with a signi®cant (50%) reduction in cell viability after only 5 days. Cells treated with the mismatch control oligo showed little, if any, cell death over the treatment period. The spA 2 -anti-hTR oligo showed a mild antisense eect although 80% of cells remained viable over the treatment period. These experiments have since been repeated on a number of occasions with U251-MG cells to test new batches of oligonucleotides, always with the same results. When other human malignant glioma cells (U373-MG, GB-1, and T98G) which express high levels of telomerase (Figure 2 ), were treated with spA 4 -anti-hTR, similar results were obtained. Thus, after 14 days from the initial treatment with spA 4 -anti-hTR, the viability of U251-MG cells, as shown by Trypan-blue exclusion assays, was suppressed in all cases. When cells treated with spA 4 -anti-hTR were ®xed and subjected to the TUNEL assay, an increased number of darkly staining nuclei indicating apoptotic cell death was detected ( Figure 5 ). These experiments clearly demonstrated that treating cells with spA 4 -anti-hTR inhibits telomerase activity and results in tumor cell death.
Treatment of normal astrocytes with anti-telomerase
To determine whether the anti-telomerase oligonucleotides had any eect on normal cells which do not express telomerase activity, we treated normal human astrocytes (P1N, kind gift of Dr BP Barna) following the same protocol used for the tumor cells. The TRAP assay was used to con®rm that P1N cells do not express telomerase activity (Figure 2 ). The results of treating P1N cells compared with a series of other glioma cell lines are shown in Figure 6 . Treatment of normal astrocytes with SpA4-anti-hTR resulted in only a mild (2 ± 3%) reduction in cell viability compared with the dramatic eect seen in the other cell lines.
Eect of antisense telomerase in vivo
Since our long term strategy is to develop a new treatment strategy, and accepting that observations in vitro do not always translate to models in vivo, we next investigated the eect of treating tumors which had been induced subcutaneously in nude mice with spA 4 -anti-hTR. In these experiments we used both U251-MG and U373-MG cells. In our initial studies we were unable to establish tumors consistently in the¯anks of nude mice by simple injection of these cell lines. However, when mixed with matrigel, tumors arose at 100% of the inoculated sites. Consequently all tumors in this treatment protocol were established in the presence of matrigel. Initially, ®ve tumors were injected directly with either spA 4 -anti-hTR or spA 4 -anti-(M6)hTR oligonucleotides every 24 h for 7 days. Prior to treatment, the two oligonucleotides were Figure 5 Comparison of TUNEL labeling of U251 cells treated with spA 4 -anti-(M6)hTR in vitro (above) and with spA 4 -anti-hTR (below) where numerous darkly staining nuclei indicative of apoptosis can be seen (arrows) Figure 6 Comparison of the viability between normal human astrocytes (P1N) and GBM cell lines treated with the spA 4 -antihTR oligo. Over the treatment period the cell viability of the P1N cells was reduced by less than 5% compared with the signi®cant eect seen in the various tumor cell lines 2-5A antisense therapy for malignant gliomas S Kondo et al coded and only decoded after the ®nal treatment and excision of the tumors. As shown in Figure 7 , spA 4 -anti-hTR signi®cantly suppressed the growth of U251-MG and U373-MG tumors when compared with spA 4 -anti-(M6)hTR treatments (P50.03 and P50.01, respectively). In the animals treated with spA 4 -antihTR, the mean tumor volume after the 7 day treatment was 36.5+5.9 and 73.3+28.1 mm 3 , for U251-MG or U373-MG cells respectively. In contrast, mean tumor volume reached 148.5+37.3 or 287.6+46.5 mm 3 in control (spA 4 -anti-(M6)hTR treated) animals. As predicted from the in vitro results, many apoptotic cells were observed in tumors treated with spA 4 -antihTR, although tumors treated with spA 4 -anti-(M6)hTR also showed a few apoptotic cells (Figure 8 ). We have now repeated and extended these observations in a second series of experiments where the tumors were treated for 14 days instead of 7 (Figure 7) . We essentially found the same eect of the oligonucleotides. Tumors treated with spA 4 -anti-hTR showed an overall 48% reduction in their size during the treatment period whereas tumors treated with spA 4 -anti-(M6)hTR showed a 87% increase in their size. These observations were con®rmed by comparing the average wet weight of the tumors in each group after treatment (54.0+28.7 mg for spA 4 -anti-hTR, and 92.0+14.7 mg for spA 4 -anti-(M6)hTR). In this second series of experiments we also included spA 2 -anti-hTR which mimicked the lack of response seen with spA 4 -anti-(M6)hTR. The group of tumors treated with distilled water alone achieved a larger mean volume than any of the groups treated with oligonucleotides suggesting a possible non-speci®c eect with spA 2 -antihTR and spA 4 -anti-(M6)hTR, although the mean wet weight of the tumors from these groups was not signi®cantly dierent. Interestingly, in the group of animals treated with spA 4 -anti-hTR the tumors showed only a marginal additional reduction in size during days 8 ± 14 of the treatment compared with the considerable eect seen in the ®rst 7 days.
Discussion
In the series of experiments presented here, we have clearly demonstrated that treating human glioma cells in vitro with antisense molecules directed against the RNA component of human telomerase results in a relatively rapid decrease in cell viability. Furthermore, treatment of experimentally induced tumors in vivo, although it is more dicult to control the eective b Figure 7 Eect of 2-5A antisense telomerase on subcutaneous xenografts in nude mice. (a) Tumors from U251-MG and U373-MG cells were established subcutaneously in nude mice. After 4 or 5 weeks when the tumors were approximately 100 mm 3 , oligonucleotides (5 nmol/20 ml sterile distilled water) were administered directly into the tumors daily for 7 days. Five mice were used in each treatment group. Tumor volume was then determined using calipers and the mean sizes+s.d. were calculated. Tumors treated with spA 4 -anti-hTR failed to grow progressively after commencement of the treatment. Those tumors treated with the spA 4 -anti-(M6)hTR control oligonucleotide continued to increase in size throughout the treatment period. *P50.01, and **P50.03. (b) When U251-MG tumors were treated for 14 days with spA 4 -anti-hTR, the ®nal tumor volume was reduced by 50% compared with the control treated tumors which show increases of 50 ± 80%. By comparison with tumor growth rate seen in tumors treated with distilled water a mild inhibitory eect can be seen for the control oligos. In these plots tumor volume was expressed as a percentage of the original starting size before treatment a 2-5A antisense therapy for malignant gliomas S Kondo et al doses delivered to the tumors, signi®cantly retards the growth of these tumors. These observations have obvious and exciting possibilities for developing a new potential treatment for human tumors. We have also clearly shown that, although antisense molecules targeting telomerase RNA have a mild growth inhibitory eect, this eect is greatly enhanced by the novel strategy of linking the antisense oligonucleotides to the 2-5A moiety which activates RNase L and degrades the target RNA, which in this case is a critical part of the telomerase enzyme. Although the eects on cell growth are striking, the mechanisms behind the eect are unknown.
The role envisioned for telomerase in tumorigenicity is mostly correlative at the moment. Because tumor cells express high levels of telomerase and most normal cells do not it is assumed that the two observations are related. Furthermore, because normal cells with a limited life span lose telomeres at each cell division it has been suggested that this phenomenon is related to cell senescence. This suggestion was supported by the recent studies of Bodnar et al. (1998) . By introducing the reverse transcriptase component (hTRT) of human telomerase into cells which normally undergo programmed senescence, they were able to extend the life span of these cells. The recent creation of null mice for telomerase function, however, suggests that this may not be the whole story (Blasco et al., 1997) since these mice survive and are fertile and their cells are as susceptible to transformation as telomerase-positive cells. This observation would argue that telomerase expression is not essential for immortalization. So why do mouse tumor cells also express high levels of telomerase? One suggestion is that, in addition to its role in telomere maintenance, telomerase is also linked to cell proliferation in some way (Broccoli et al., 1996) and so is co-selected in tumor cells which grow rapidly. Indeed, in our study of brain tumors it is only the very aggressive glioma tumors which express telomerase and astrocytomas do not (unpublished observations). Blasco et al. (1997) were quick to point out that mouse cells are dierent to human cells particularly in their capacity for spontaneous transformation. Although one explanation for this is that they do not require so many genetic mutations to transform, an alternative explanation is that, compared with human cells, they possess fewer endogenous control mechanisms to detect and eliminate potential tumor precursor cells. At present we have not adapted this technology to the treatment of mouse tumor cells because murine RNAse L requires a 5'-diphosphate on 2-5A to be optimally activated whereas 2-5A antisense is monophosphorylated (Krause et al., 1986) . In contrast, human RNase L is fully activated by 5' monophosphorylated 2-5A . However, if telomerase is part of other, as yet unknown, cellular pathways possibly involved in the control of cell growth, this might explain our observation that interfering with its function could trigger a surveillance mechanism which in turn commits the cell to an apoptotic pathway of cell death. Such a mechanism would account for the rapid reduction in cell proliferation seen in the anti-hTR treated cells and, since a signi®cant eect is seen in the glioma cells after only 5 ± 7 days, it is unlikely that cell death is related to telomere erosion since these cells would not have undergone enough cell divisions to signi®cantly shorten their telomeres. That telomerase is related to cell proliferation rather than malignant transformation was demonstrated in epithelial cells by Beliar et al. (1997) , further supporting the possibility that interfering with telomerase activity can aect other aspects of the cell cycle than telomere length. Recently a connection between the expression of the Bcl-2 gene, which protects cells against apoptosis and telomerase activity was demonstrated (Mandal and Kumar, 1997) . HeLa cells transfected with Bcl-2 showed 5 ± 6-fold overexpression of this gene and increased activity of telomerase. In contrast, when IL-2 dependent cells were deprived of IL-2, expression levels of both Bcl-2 and telomerase were reduced. There is further evidence that the mere presence of telomerase may not be essential for immortality (Bryan et al., 1995) since somatic cell hybrids between telomerase positive cells and telomerase-negative cells usually show that senescence is dominant over the malignant phenotype.
Despite our limited current understanding of the mechanisms linking telomerase, immortalization and Figure 8 In situ end-labeling of DNA in subcutaneous xenografts of nude mice. After treatment with oligonucleotides (5 nmol, every day) for 7 days, the mice were sacri®ced and the subcutaneous mass was removed, frozen, and sectioned on a cryostat. The tumor specimens from U251-MG cells were counterstained by hematoxylin and eosin following the TUNEL technique. Arrows show representatives of tumor cells positive for DNA fragmentation (6400). (above) spA 4 -anti-(M6)hTR, 7 Day; (below) spA 4 -anti-hTR, 7 Day apoptosis, the demonstration that targeting telomerase RNA can kill tumor cells opens the way to extend and develop strategies to use this as an eective treatment against cancer. To this end one of our future goals will be to improve the treatment regimens and develop more eective in vivo treatment protocols using the 2-5A antisense technology.
Materials and methods
Oligonucleotide synthesis and RT ± PCR for telomerase RNA Chimeric oligonucleotides were synthesized on solid supports and puri®ed as described previously Lesiak et al., 1993; Xiao et al., 1994 Xiao et al., , 1996 Cirino et al., 1997) . Tumor cells were seeded at 3610 5 cells/well (3 ml) in 6-well plates and incubated overnight at 378C. Cells were then treated with oligonucleotides (5 mM). Five hours later total RNA was isolated by using Trizol solution (GIBCO BRL, Grand Island, NY). Expression of telomerase RNA was determined with RT ± PCR. The RNA was reverse transcribed into complementary DNA (cDNA) with random oligos used as a primer, and then the cDNA was diluted three times with buer 106PCR buer (Perkin-Elmer, Norwalk, CT) at a ®nal concentration of 1 : 4. The DNA at each dilution was ampli®ed using primers to antisense and sense sequences on opposite sides of the human telomerase RNA sequence, 5'-TTTGTCTAACCCTAACTGAGAAGG-3' and 5'-TGTGAGCCGAGTCCTGGGTGCACG-3', respectively, or to the GAPDH coding sequence, 5'-ACCACCATGGA-GAAGGCTGG-3' and 5'-CGTAGGACCCGATGT-GACTC-3', respectively, producing DNA fragments of 400 bp for telomerase cDNA and 508 bp for the GAPDH cDNA, respectively. The PCR went for 30 cycles (948C, 1 min; 558C, 1 min; 728C, 2 min) for telomerase and 30 cycles (948C, 1 min, 608C, 1 min; 748C, 3 min) for GAPDH. The PCR products were analysed by 1.2% agarose gel electrophoresis and ethidium bromide staining.
TRAP assay
The telomerase (TRAP) assay was performed using the method described previously (Kim et al., 1994) with some minor modi®cations. Tumor cells were seeded at 10 4 cells/ well (0.1 ml) in 96-well microplate and incubated overnight at 378C. Prior to the TRAP assay, cells were washed once in PBS, and homogenized in 50 ml of ice-cold lysis buer (10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM PMSF, 5 mM b-mercaptoethanol, 0.5% CHAPS, 10% glycerol). After 30 min incubation on ice, the lysates were centrifuged at 12 000 g for 30 min at 48C, and the supernatant was rapidly frozen and stored 7808C. The concentration of protein was measured using the BioRad Protein Assay (Richmond, CA), and an aliquot of extract containing 5 mg/ml of protein was used for each telomerase assay. For RNase treatment, 5 ml of extract was incubated with 1 ml RNase A (1 mg/ml) for 30 min at 258C. Two ml of each extract was assayed in 50 ml of reaction mixture containing 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 63 mM KCl, 0.05% Tween-20, 1 mM EGTA, 50 mM deoxynucleoside triphosphates, 0.2 ± 0.4 ml of [a-32 P]dCTP (10 mCi/ml, 300 Ci/mM), 0.1 mg of TS oligonucleotides (5'-AATCCGTCGAGCAGAGTT-3'), 1 mg of T4 gene 32 protein (Boehringer Mannheim Biochemicals, Indianapolis, IN) and 2 units of Taq DNA polymerase (Boehringer Mannheim). After a 10 min incubation at room temperature for telomerase-mediated extension of the TS primer, 0.1 mg of CX oligonucleotides (5'-CCCTTACCCT-TACCCTTACCCTAA-3') was added. The reaction mixture was then subjected to PCR ampli®cation in a thermal cycler with 30 cycles 948C for 30 s, 508C for 30 s, and 728C for 1.5 min. The PCR product was electrophoresed in 0.56 tris borate EDTA on a 10% polyacrylamide gel. The gels were then dried, and autoradiography was performed for 24 h at 7708C. Radioactivity was also quantitated with a Molecular Dynamics PhosphorImager (Sunnyvale, CA).
Cell viability assay
The cytotoxic eect of 2-5A antisense on tumor cells was determined using the trypan blue dye exclusion assay. Tumor cells were seeded at 10 4 cells/well (0.1 ml) in 96-well at-bottomed plates and incubated overnight at 378C. Then, oligonucleotides (5 mM) were added into cells every 12 h. In this procedure, the culture medium was removed and the oligos added directly to the cells for 30 ± 60 s to facilitate uptake, whereafter the culture medium was added. During this treatment period the cells were harvested when the controls became con¯uent and 25% of the total was examined microscopically to determine the percentage of viable cells, another 25% was reseeded to continue treatment and the remaining 50% were used for the TRAP assay.
TUNEL assay
To further determine whether treatment with oligonucleotides induced apoptosis, tumor cells and tissues were stained by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) technique using Apo-Tag kit (Oncor Inc., Gaithersburg, MD).
In vivo treatment
Tumor cells (1.0610 6 cells in 0.1 ml serum free DMEM and 0.1 ml Matrigel) were injected subcutaneously into the right¯ank of 8 ± 12 week-old female Balb/c nude mice (®ve mice for each treatment group). Tumor growth was monitored using calipers every 2-or 3-days. Tumor volume (V) was calculated as (L6W 2 )/ 2 , where L=length (mm) and W=width (mm). Oligonucleotide treatment was initiated when the tumors reached an average tumor volume of 60 ± 100 mm 3 (about 4 ± 5 weeks after injection). Oligonucleotides (5 nmol/20 ml sterile distilled water) were administered by injecting them directly into the tumor every 24 h for 7 ± 14 days. Mice were sacri®ced by cervical dislocation the day after the ®nal injection and the tumors were removed, frozen rapidly and 12 mm sections were prepared for histological studies. During all of these experiments, which were approved by the CCF Research Programs Committee, the animals were housed and handled in accordance with the National Institutes of Health guidelines.
